Brief: Q32 Bio Sells Complement Inhibitor Adx-097
01/12/2025 13:03
Dec 1 (Reuters) - Q32 BIO SELLS COMPLEMENT INHIBITOR ADX-097 Q32 BIO INC - $12 MILLION PAYMENTS EXPECTED TO EXTEND CASH RUNWAY INTO SECOND HALF OF 2027 Q32 BIO INC - ELIGIBLE FOR UP TO $592 MILLION INCLUDING ROYALTIES Source text: ID:nPn4S4bM2a ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Q32 Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Q32 Bio Reports Second Quarter 2026 Financial Results And Provides Corporate Update
Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Q32 Bio Inc expected to post a loss of 54 cents a share - Earnings Preview